Trial · NCT01632423
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
NCT01632423, Completed, Allergan; results first posted 2012-09-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). Trials, record NCT01632423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01632423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
- NCT number
- NCT01632423
- Status
- Completed
- Enrollment
- 10,337 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- bimatoprost 0.01%
- First posted
- 2012-07-03
- Last updated
- 2012-09-21
- Results first posted
- 2012-09-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Intraocular Pressure (IOP) | Baseline, 14 Weeks | IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement. |
| Secondary | Patient Assessment of Tolerability Using a 4-Point Scale | 14 Weeks | Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported. |
| Secondary | Physician Assessment of Tolerability Using a 4-Point Scale | 14 Weeks | Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported. |
| Secondary | Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks | 14 Weeks | Patients who discontinued Lumigan® prior to 14 weeks was assessed as Yes or No. |
| Secondary | Patients Who Will Continue Use of Lumigan® After 14 Weeks | 14 Weeks | Patients who will continue use of Lumigan® after 14 weeks was assessed as Yes or No. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Intraocular Pressure (IOP) | Baseline, 14 Weeks | All enrolled patients with complete data for this outcome measure | Millimeters of Mercury (mmHg) | MEDIAN |
| SECONDARY | Patient Assessment of Tolerability Using a 4-Point Scale | 14 Weeks | All enrolled patients with complete data for this outcome measure | Participants | NUMBER |
| SECONDARY | Physician Assessment of Tolerability Using a 4-Point Scale | 14 Weeks | All enrolled patients with complete data for this outcome measure | Participants | NUMBER |
| SECONDARY | Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks | 14 Weeks | All enrolled patients with complete data for this outcome measure | Participants | NUMBER |
| SECONDARY | Patients Who Will Continue Use of Lumigan® After 14 Weeks | 14 Weeks | All enrolled patients with complete data for this outcome measure | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Intraocular Pressure (IOP) | POAG or OHT | Baseline - Right Eye (N=10062) | 20.0 | Inter-Quartile Range 17.0 to 23.0 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Intraocular Pressure (IOP) | POAG or OHT | Change from Baseline at 14 Wks-Rt Eye (N=10062) | -4.0 | Inter-Quartile Range -5.0 to -3.0 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Intraocular Pressure (IOP) | POAG or OHT | Baseline - Left Eye (N=10074) | 20.0 | Inter-Quartile Range 17.0 to 23.0 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Intraocular Pressure (IOP) | POAG or OHT | Change from Baseline at 14 Wks-Lft Eye (N=10074) | -4.0 | Inter-Quartile Range -5.0 to -3.0 | Millimeters of Mercury (mmHg) |
| Patient Assessment of Tolerability Using a 4-Point Scale | POAG or OHT | 9227 | Participants | ||
| Physician Assessment of Tolerability Using a 4-Point Scale | POAG or OHT | 9571 | Participants | ||
| Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks | POAG or OHT | 642 | Participants | ||
| Patients Who Will Continue Use of Lumigan® After 14 Weeks | POAG or OHT | 9121 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | POAG or OHT | 10,337 | |
| Overall Study | COMPLETED | POAG or OHT | 10,091 | |
| Overall Study | NOT COMPLETED | POAG or OHT | 246 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | POAG or OHT | 1 | 10,337 | |
| serious | Asthma | Respiratory, thoracic and mediastinal disorders | POAG or OHT | 1 | 10,337 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | POAG or OHT | ||
| Total, other adverse events | POAG or OHT | 0 | 10,337 |
| Total, serious adverse events | POAG or OHT | 2 | 10,337 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01632423
GET https://conductscience.org/api/trials/v1/NCT01632423/registered